-
Earnings Scheduled For August 4, 2014
Monday, August 4, 2014 - 5:14am | 959Alere (NYSE: ALR) is expected to report its Q2 earnings at $0.58 per share on revenue of $747.55 million. Cardinal Health (NYSE: CAH) is projected to report its Q4 earnings at $0.81 per share on revenue of $21.88 billion. Marathon Oil (NYSE: MRO) is estimated to post its Q2 earnings at $0.75 per...
-
La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock
Tuesday, July 22, 2014 - 4:02pm | 433La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its...
-
Benzinga's Volume Movers
Tuesday, July 15, 2014 - 10:36am | 195La Jolla Pharmaceutical Co (NASDAQ: LJPC) shares moved up 16.59% to $12.65. The volume of La Jolla Pharmaceutical shares traded was 2646% higher than normal. La Jolla Pharmaceutical reported positive pre-clinical data for oral galectin-3 inhibitor in NASH. Rockwood Holdings (NYSE: ROC) shares rose...
-
Morning Market Movers
Tuesday, July 15, 2014 - 9:46am | 249Codexis (NASDAQ: CDXS) rose 82.27% to $2.57 after the company announced the signing of a platform technology license agreement with GlaxoSmithKline (NYSE: GSK). La Jolla Pharmaceutical Co (NASDAQ: LJPC) surged 22.03% to $13.24 after the company reported positive pre-clinical data for oral galectin-...
-
US Stock Futures Flat; All Eyes On Fed Minutes
Wednesday, July 9, 2014 - 7:40am | 422Pre-open movers US stock futures traded mostly flat in early pre-market trade. The Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average dropped 5 points to 16,855.00, while the Standard & Poor's 500 index futures...
-
Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes
Wednesday, July 9, 2014 - 7:03am | 733Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211...
-
La Jolla Pharmaceutical Company Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension
Tuesday, July 8, 2014 - 4:02pm | 489La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the Company plans to begin a phase 3 registration program for LJPC-501 for the treatment of...
-
Benzinga's Volume Movers
Tuesday, June 24, 2014 - 10:41am | 160Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor met the primary endpoint. TG Therapeutics (NASDAQ:...
-
Ligand to Present Positive Data from Phase 1 Study of Effect of SERN Lasofoxifene
Monday, June 23, 2014 - 8:03am | 319Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study...
-
UPDATE: Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases
Wednesday, May 14, 2014 - 8:35am | 1245Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca plc (NYSE: AZN), for the development of products to treat dyslipidemia, including...
-
UPDATE: Ligand Pharma Announces Milestone from Sage Therapeutics for SAGE-547
Monday, May 12, 2014 - 8:05am | 268Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a...
-
Morning Market Movers
Monday, May 5, 2014 - 9:45am | 206Hyperdynamics (NYSE: HDY) climbed 38.26% to $2.06 after the company announced the lifting of declaration of Force Majeure by Tullow. B/E Aerospace (NASDAQ: BEAV) gained 9.88% to $97.75 after the company reported that it is exploring strategic alternatives for the company. Arotech (NASDAQ: ARTX)...
-
Spectrum Pharmaceuticals' Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Wednesday, April 23, 2014 - 7:12am | 585CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene glycol, an ingredient in currently available products which has been associated with renal and...
-
Morning Market Movers
Monday, April 14, 2014 - 9:38am | 449Aspen Insurance Holdings (NYSE: AHL) rose 18.67% to $46.72 after Endurance Specialty Holdings (NYSE: ENH) offered to buy Aspen Insurance for $47.50 per share in a cash and stock deal. Goodrich Petroleum (NYSE: GDP) jumped 18.32% to $21.77 after the company announced the completion of its Blades...
-
Stocks Hitting 52-Week Highs
Tuesday, March 11, 2014 - 10:23am | 127La Jolla Pharmaceutical Co (NASDAQ: LJPC) shares touched a new 52-week high of $18.86 on positive Phase 2 GCS-100 trial results in chronic kidney disease. FuelCell Energy (NASDAQ: FCEL) shares rose 16.54% to reach a new 52-week high of $4.58 after the company reported Q1 results. FuelCell posted...